CELZ vs. TTNP, CHRO, FRTX, GMDA, TCON, GENE, PALI, FNCH, NSTGQ, and BCDA
Should you be buying Creative Medical Technology stock or one of its competitors? The main competitors of Creative Medical Technology include Titan Pharmaceuticals (TTNP), Chromocell Therapeutics (CHRO), Fresh Tracks Therapeutics (FRTX), Gamida Cell (GMDA), TRACON Pharmaceuticals (TCON), Genetic Technologies (GENE), Palisade Bio (PALI), Finch Therapeutics Group (FNCH), NanoString Technologies (NSTGQ), and BioCardia (BCDA). These companies are all part of the "biological products, except diagnostic" industry.
Creative Medical Technology (NASDAQ:CELZ) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.
Creative Medical Technology has a net margin of 0.00% compared to Titan Pharmaceuticals' net margin of -2,014.71%. Creative Medical Technology's return on equity of -41.48% beat Titan Pharmaceuticals' return on equity.
Titan Pharmaceuticals received 264 more outperform votes than Creative Medical Technology when rated by MarketBeat users. However, 68.93% of users gave Creative Medical Technology an outperform vote while only 57.26% of users gave Titan Pharmaceuticals an outperform vote.
Creative Medical Technology has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.
Creative Medical Technology has higher revenue and earnings than Titan Pharmaceuticals. Creative Medical Technology is trading at a lower price-to-earnings ratio than Titan Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Titan Pharmaceuticals had 1 more articles in the media than Creative Medical Technology. MarketBeat recorded 3 mentions for Titan Pharmaceuticals and 2 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 0.50 beat Titan Pharmaceuticals' score of -0.03 indicating that Creative Medical Technology is being referred to more favorably in the media.
1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are held by institutional investors. 3.3% of Creative Medical Technology shares are held by company insiders. Comparatively, 24.9% of Titan Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Creative Medical Technology beats Titan Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Creative Medical Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CELZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Creative Medical Technology Competitors List
Related Companies and Tools
